|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.12.25 - 12:36
|
EC approves Incyte′s Minjuvi combo for follicular lymphoma (PBR)
|
|
|
FL is the most common slow-growing B-cell non-Hodgkin lymphoma form. Minjuvi is a humanised, fragment crystallisable-modified cytolytic monoclonal antibody targeting cluster of differentiation 19. The EC approval follows
The post EC approves Incyte's Minjuvi combo for follicular lymphoma appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.12.25 - 14:33
|
Incyte Announces Change to its Board of Directors (Business Wire)
|
|
|
WILMINGTON, Del.--(BUSINESS WIRE)--$INCY--Incyte (Nasdaq:INCY) today announced the resignation of Hervé Hoppenot from the Company's Board of Directors, effective immediately. As previously announced, Mr. Hoppenot had been serving as an advisor to the Chief Executive Officer (CEO) and as a member of the Board during a planned transition period.
Mr. Hoppenot joined Incyte in 2014 and previously served as Chairman and CEO.
“On behalf of the Board of Directors, I would like to thank Hervé for his steadfast leadership, vision and guidance throughout his tenure, which helped grow Incyte into a leading, innovative company,” said Julian Baker, Managing Partner of Baker Bros. Advisors LP and Incyte's Chairman of the Board. “Hervé leaves a lasting impact on the company and its legacy of delivering transformative science and medicines for patients.”
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical need...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
